Since its release in late 2020, the FDA’s Memorandum of Understanding with states on interstate shipments of compounding medications has been subject to concerns from compounding pharmacies and state Boards of Pharmacies. The decision of whether or not to sign the MOU has forced states to make a no-win decision: if they sign the MOU, the state board of pharmacy must assume a significant – and unfunded – administrative burden. If the state doesn’t sign, compounding pharmacies will be restricted to shipping out-of-state no more than five percent of all compounded medications they dispense (including patient-specific meds) – limiting patient access to compounded meds and may lead to pharmacy closings.
Join leaders from the Alliance for Pharmacy Compounding, who are spearheading efforts to address the flaws of the MOU, for a briefing about what the MOU will mean for your pharmacy and the patients you serve – as well as what APC is doing to combat it.
Scott Brunner, CAE
Chief Executive Officer
Alliance for Pharmacy Compounding
David Pore, Esq.
Government Affairs Counsel, Alliance for Pharmacy Compounding
Partner, Hance Scarborough LLP